May 16, 2020

Glenmark to Build $100M US Manufacturing Facility

Glenmark Pharmaceuticals
Manufacturing facility
US Manufac
Glen White
2 min
India’s Glenmark Pharmaceuticals, one of the global leaders in pharmaceutical manufacturing, is planning to build a $100 million state of the art facility to serve the United States market.
Indias Glenmark Pharmaceuticals, one of the global leaders in pharmaceutical manufacturing, is planning to build a $100 million state of the art facilit...

India’s Glenmark Pharmaceuticals, one of the global leaders in pharmaceutical manufacturing, is planning to build a $100 million state of the art facility to serve the United States market.  Glenmark is hoping this move will help them shed some of the negative publicity that Indian pharmaceutical companies have received this past year due to quality issues.  It is also hoping to solidify its future growth strategy, the Times of India reported.

This will be Glenmark’s first American manufacturing facility.  The company already boasts roughly $65 billion in U.S. generic drug sales and six research and development centers.  They currently operate 14 manufacturing facilities in four countries, including a new antibody facility in Switzerland that opened in June.

“The U.S. is a key market for Glenmark, and it’s important to have a manufacturing base here to serve its growing business,” a Glenmark official told the Times of India, adding that a specific location has not yet been determined.
Glenmark is not the first Indian pharma business to come to America.  Several companies have already opened plants in the United States or have acquired American companies.

Mumbai-based Wockhardt opened its New Jersey based facility in 2004, back when it only had three FDA-approved products under its belt.  The company has seen significant growth since then, particularly at that facility, which now represents over 41 percent of Wockhardt Ltd.’s global business.  Wockhardt has more than 257 NDC’s spanning over 66 different product families.
Sun Pharma’s United States Subsidiary Caraco Pharmaceuticals has launched seven new drugs in the past three months including generic versions of Ticlid(R) and TEMODAR(R).  Indian companies Ranbaxy and Dr. Reddy’s have also capitalized on U.S.-based manufacturing facilities.
A number of Indian companies operating in America have had their share of trouble with the United States Food and Drug Administration, including Ranbaxy, whose exports to the U.S. have been banned since 2008.  Last month, Dr. Reddy’s was forced to recall 13,000 bottles of its hypertension drug because it failed dissolution tests.
“Due to quality issues, more domestic companies are trying to de-risk strategy by looking at setting up facilities close to the U.S. soil, in Canada and Mexico,” Sujay Shetty, leader-pharma, PwC India, explained. “Now, with technological advances and other government incentives, the cost of manufacturing in the U.S., particularly injectables, has also been reduced, which is a big draw for these companies.”

Share article

Jun 16, 2021

Fluent.ai x BSH: Voice Automating the Assembly Line

Fluentai
BSH
AI
Technology
2 min
Fluent.ai and BSH announce plans to bring speech-to-intent AI to the assembly line that will increase factory efficiency and improve worker ergonomics

Fluent.ai has deployed its voice recognition solutions in one of BSH’s German factories. BSH leads the market in producing connected appliances—its brands include Bosch, Siemens, Gaggenau, NEFF, and Thermador, and with this new partnership, the company intends to cut transition time in its assembly lines. 

 

According to BSH, voice automation will yield 75-100% efficiency gains—but it’s the collaboration between the two companies that stands out. ‘After considering 11 companies for this partnership, we chose Fluent.ai because of their key competitive differentiators’, explained Ion Hauer, Venture Partner at BSH Startup Kitchen.

 

What Sets Fluent.ai Apart? 

After seven years of research, the company developed a wide range of artificial intelligence (AI) software products to help original equipment manufacturers (OEM) expand their services. Three key aspects stood out to BSH, which operates across the world and in unique factory environments.  

 

  • Robust noise controls. The system can operate even in loud conditions. 
  • Low latency. The AI understands commands quickly and accurately. 
  • Multilingual support. BSH can expand the automation to any of its 50+ country operations. 

 

How Voice Automation Works

Instead of pressing buttons, BSH factory workers will now be able to speak into a headset fitted with Fluent.ai’s voice recognition technology. After uttering a WakeWord, workers can use a command to start assembly line movement. As the technology is hands-free, workers benefit from less physical strain, which will both reduce employee fatigue and boost line production. 

 

‘Implementing Fluent’s technology has already improved efficiencies within our factory, with initial implementation of the solution cutting down the transition time from four seconds to one and a half”, said Markus Maier, Project Lead at the BSH factory. ‘In the long run, the production time savings will be invaluable’. 

 

Future Global Adoption 

In the coming years, BSH and Fluent.ai will continue to push for artificial intelligence on factory lines, pursuing efficiency, ergonomics, and a healthy work environment. ‘We started with Fluent.ai on one factory assembly line, moved to three, and [are now] considering rolling the technology out worldwide’, said Maier. 

 

Said Probal Lala, Fluent.ai’s CEO: ‘We are thrilled to be working with BSH, a company at the forefront of innovation. Seeing your solution out in the real world is incredibly rewarding, and we look forward to continuing and growing our collaboration’. 

 

 

Share article